OCX Quote, Financials, Valuation and Earnings

Fonar has a net margin of -11733.04% compared to OncoCyte's net margin of 12.56%. OncoCyte's return on equity of -211.42% beat Fonar's return on equity of 6.13%.

OncoCyte has a consensus price target of $4.13, signalling upside risk potential of 98.32%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

OncoCyte has a beta of 0.897, which suggesting that the stock is 10.313% less volatile than S&P 500. In comparison Fonar has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.214%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $115K, which are smaller than Fonar quarterly revenues of $25M. OncoCyte's net income of -$13.5M is lower than Fonar's net income of $3.1M. Notably, OncoCyte's price-to-earnings ratio is -- while Fonar's PE ratio is 10.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 31.62x versus 0.96x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs has a net margin of -11733.04% compared to OncoCyte's net margin of -209.38%. OncoCyte's return on equity of -211.42% beat ProPhase Labs's return on equity of -59.59%.

OncoCyte has a consensus price target of $4.13, signalling upside risk potential of 98.32%. On the other hand ProPhase Labs has an analysts' consensus of $21.00 which suggests that it could grow by 3427.63%. Given that ProPhase Labs has higher upside potential than OncoCyte, analysts believe ProPhase Labs is more attractive than OncoCyte.

OncoCyte has a beta of 0.897, which suggesting that the stock is 10.313% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.304, suggesting its less volatile than the S&P 500 by 130.392%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $115K, which are smaller than ProPhase Labs quarterly revenues of $3.1M. OncoCyte's net income of -$13.5M is lower than ProPhase Labs's net income of -$6.6M. Notably, OncoCyte's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 31.62x versus 0.86x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte has a net margin of -11733.04% compared to OncoCyte's net margin of 13.08%. OncoCyte's return on equity of -211.42% beat Veracyte's return on equity of -0.84%.

OncoCyte has a consensus price target of $4.13, signalling upside risk potential of 98.32%. On the other hand Veracyte has an analysts' consensus of $43.22 which suggests that it could grow by 6.51%. Given that OncoCyte has higher upside potential than Veracyte, analysts believe OncoCyte is more attractive than Veracyte.

OncoCyte has a beta of 0.897, which suggesting that the stock is 10.313% less volatile than S&P 500. In comparison Veracyte has a beta of 1.706, suggesting its more volatile than the S&P 500 by 70.591%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $115K, which are smaller than Veracyte quarterly revenues of $115.9M. OncoCyte's net income of -$13.5M is lower than Veracyte's net income of $15.2M. Notably, OncoCyte's price-to-earnings ratio is -- while Veracyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 31.62x versus 7.24x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

XWELL has a net margin of -11733.04% compared to OncoCyte's net margin of -56.4%. OncoCyte's return on equity of -211.42% beat XWELL's return on equity of -71.82%.

OncoCyte has a consensus price target of $4.13, signalling upside risk potential of 98.32%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 460%. Given that XWELL has higher upside potential than OncoCyte, analysts believe XWELL is more attractive than OncoCyte.

OncoCyte has a beta of 0.897, which suggesting that the stock is 10.313% less volatile than S&P 500. In comparison XWELL has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.765%.

OncoCyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OncoCyte pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

OncoCyte quarterly revenues are $115K, which are smaller than XWELL quarterly revenues of $8.4M. OncoCyte's net income of -$13.5M is lower than XWELL's net income of -$4.8M. Notably, OncoCyte's price-to-earnings ratio is -- while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OncoCyte is 31.62x versus 0.16x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.